Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMMP NASDAQ:SCYX NASDAQ:VCNX NASDAQ:XERS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMMPPrima BioMed$0.36-3.8%$0.45$0.29▼$3.53$54.57M2.21829,534 shs231,647 shsSCYXSCYNEXIS$4.09$6.51$3.93▼$10.48$22.83M1.0561,978 shs104,662 shsVCNXVaccinex$1.00-2.0%$1.02$0.31▼$1.50$2.60M1.13,716 shs1,459 shsXERSXeris Biopharma$6.90+0.3%$6.23$4.40▼$10.08$1.19B0.781.51 million shs1.47 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMMPPrima BioMed-3.81%-3.44%-31.46%-14.27%-79.17%SCYXSCYNEXIS0.00%-6.19%-30.91%-43.18%-34.87%VCNXVaccinex-1.96%-10.74%-9.09%-3.81%+40.85%XERSXeris Biopharma+0.29%+6.15%+10.58%+27.07%+56.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMMPPrima BioMed$0.36-3.8%$0.45$0.29▼$3.53$54.57M2.21829,534 shs231,647 shsSCYXSCYNEXIS$4.09$6.51$3.93▼$10.48$22.83M1.0561,978 shs104,662 shsVCNXVaccinex$1.00-2.0%$1.02$0.31▼$1.50$2.60M1.13,716 shs1,459 shsXERSXeris Biopharma$6.90+0.3%$6.23$4.40▼$10.08$1.19B0.781.51 million shs1.47 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMMPPrima BioMed-3.81%-3.44%-31.46%-14.27%-79.17%SCYXSCYNEXIS0.00%-6.19%-30.91%-43.18%-34.87%VCNXVaccinex-1.96%-10.74%-9.09%-3.81%+40.85%XERSXeris Biopharma+0.29%+6.15%+10.58%+27.07%+56.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMMPPrima BioMed 1.75Reduce$5.501,444.08% UpsideSCYXSCYNEXIS 2.00Hold$24.00486.80% UpsideVCNXVaccinex 0.00N/AN/AN/AXERSXeris Biopharma 2.43Hold$10.8056.52% UpsideCurrent Analyst Ratings BreakdownLatest IMMP, XERS, SCYX, and VCNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2026SCYXSCYNEXIS Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/11/2026XERSXeris Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)(Data available from 6/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMMPPrima BioMed$6.69M7.85N/AN/A$0.63 per share0.57SCYXSCYNEXIS$20.60M1.11N/AN/A$9.07 per share0.45VCNXVaccinex$388K6.70N/AN/A($2.59) per share-0.39XERSXeris Biopharma$291.85M4.08$0.10 per share68.69$0.08 per share86.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMMPPrima BioMed-$39.78MN/AN/AN/AN/AN/AN/AN/A9/2/2026 (Estimated)SCYXSCYNEXIS-$8.61M-$3.84N/AN/AN/A-41.79%-57.16%-39.48%8/12/2026 (Estimated)VCNXVaccinex-$20.25M-$48.27N/AN/AN/AN/AN/A-383.58%8/10/2026 (Estimated)XERSXeris Biopharma$550K$0.06115.0020.29N/A3.81%735.00%3.24%8/6/2026 (Estimated)Latest IMMP, XERS, SCYX, and VCNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026SCYXSCYNEXIS-$0.80-$3.36-$2.56-$0.42$0.08 millionN/A5/7/2026Q1 2026XERSXeris Biopharma-$0.0027$0.01+$0.0127$0.01$79.83 million$83.13 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIMMPPrima BioMedN/AN/AN/AN/AN/ASCYXSCYNEXISN/AN/AN/AN/AN/AVCNXVaccinexN/AN/AN/AN/AN/AXERSXeris BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMMPPrima BioMedN/A2.97N/ASCYXSCYNEXISN/A3.943.94VCNXVaccinexN/A0.770.77XERSXeris Biopharma17.002.121.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMMPPrima BioMed2.32%SCYXSCYNEXIS54.37%VCNXVaccinex50.11%XERSXeris Biopharma42.75%Insider OwnershipCompanyInsider OwnershipIMMPPrima BioMed3.07%SCYXSCYNEXIS4.09%VCNXVaccinex51.50%XERSXeris Biopharma4.35%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMMPPrima BioMed2,021147.37 million142.85 millionOptionableSCYXSCYNEXIS605.58 million5.36 millionOptionableVCNXVaccinex402.60 million1.26 millionNo DataXERSXeris Biopharma290172.64 million165.13 millionOptionableIMMP, XERS, SCYX, and VCNX HeadlinesRecent News About These CompaniesXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Consensus Rating of "Hold" from BrokeragesJune 13, 2026 | americanbankingnews.comJim Cramer Blesses a Caller’s Speculative Investment in Xeris BiopharmaJune 12, 2026 | insidermonkey.comXeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®June 11, 2026 | businesswire.comXeris to retire $23M of convertible notes through exchange agreementsJune 11, 2026 | seekingalpha.comXeris Biopharma Announces Private Exchange of Convertible NotesJune 11, 2026 | finance.yahoo.comXeris Biopharma Announces Debt Reduction via Note ExchangesJune 11, 2026 | tipranks.comAnalyzing Amylyx Pharmaceuticals (NASDAQ:AMLX) and Xeris Biopharma (NASDAQ:XERS)June 7, 2026 | americanbankingnews.comXeris Biopharma (NASDAQ:XERS) Director Sells $91,350.00 in StockJune 6, 2026 | insidertrades.comXeris Biopharma Shareholders Elect Directors and Ratify AuditorJune 5, 2026 | tipranks.comXeris Biopharma (NASDAQ:XERS) Insider Beth Hecht Sells 16,667 SharesJune 3, 2026 | insidertrades.comXeris Looks Ridiculously Cheap If Growth Forecasts Are Even Halfway RightMay 30, 2026 | seekingalpha.comUBS Group AG Reduces Position in Xeris Biopharma Holdings, Inc. $XERSMay 22, 2026 | marketbeat.comShareholders Will Be Pleased With The Quality of Xeris Biopharma Holdings' (NASDAQ:XERS) EarningsMay 15, 2026 | finance.yahoo.comXeris Biopharma Quality Draws Market Attention Through Growth SignalsMay 15, 2026 | kalkinemedia.comKResults: Xeris Biopharma Holdings, Inc. Confounded Analyst Expectations With A Surprise ProfitMay 9, 2026 | uk.finance.yahoo.comXeris Biopharma Holdings (XERS) Is Up 8.2% After Swing to Q1 Profitability - What's ChangedMay 8, 2026 | finance.yahoo.comXeris (XERS) Q1 2026 Earnings Call TranscriptMay 7, 2026 | aol.comAXeris Biopharma: Q1 Earnings SnapshotMay 7, 2026 | wtop.comWXeris Biopharma Reports First Quarter 2026 Financial ResultsMay 7, 2026 | finance.yahoo.comXeris Biopharma Holdings, Inc. (XERS) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comXeris Biopharma (XERS) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesMay 7, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMMP, XERS, SCYX, and VCNX Company DescriptionsPrima BioMed NASDAQ:IMMP$0.36 -0.01 (-3.81%) Closing price 06/16/2026 04:00 PM EasternExtended Trading$0.36 +0.00 (+1.07%) As of 06/16/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.SCYNEXIS NASDAQ:SCYX$4.09 0.00 (0.00%) Closing price 06/16/2026 04:00 PM EasternExtended Trading$4.12 +0.03 (+0.73%) As of 06/16/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.Vaccinex NASDAQ:VCNX$1.00 -0.02 (-1.96%) As of 06/16/2026 01:53 PM EasternVaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.Xeris Biopharma NASDAQ:XERS$6.90 +0.02 (+0.29%) Closing price 06/16/2026 04:00 PM EasternExtended Trading$6.91 +0.01 (+0.14%) As of 06/16/2026 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Strategy’s Bitcoin Rally Has a Hidden Engine Is Lennar Finally Turning the Corner After Its Housing Slump? Plot Twist: How the $110B Paramount-Warner Deal Rewrites Media AST SpaceMobile Announces Launch Date for Its Next 3 BlueBird Satellites Insiders Sell Top Tech Plays: Should Investors Buy, Sell, or Hold? What's Behind the Social Media Controversy Surrounding IonQ? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
